NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-08-31
Reading SOLV? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Free cash flow of approximately $200 million in 2026: FCF guidance $200M-$300M vs $200M target.
Solventum aims for steady sales growth of 2% to 3% in 2026. Adjusted EPS is guided between $6.40 and $6.60, showing solid profit growth. The company targets about $200 million in free cash flow for 2026. Its valuation is cheap compared to peers with a P/E of 12.2 versus 28.4 for the sector.
AI disruption fears and litigation risks could hurt earnings. Free cash flow was negative $273 million in Q1, far from the $200 million target. Revenue fell 3% year-over-year in Q1, and guidance was cut. These issues may pressure profit margins and growth.
The price is about 13% below our fair value near $88, reflecting modest 2% revenue growth expected by analysts. Our fair value is slightly below the Street median of $92, indicating the market prices in moderate growth but also some risks.
Breaks if: adjusted EPS falls below $6.40 in FY26
Breaks if: free cash flow remains negative or below $100 million in FY26
Breaks if: organic sales growth falls below 2.0% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder in the healthcare sector. The current thesis is supported by recent strong financial performance and a focus on organic growth, although there are some mixed signals regarding management priorities.
The market seems to have priced in a low expectations gap, indicating that SOLV is viewed as cheap compared to its peers. There is a low level of fragility in the current market regime, suggesting stability in its valuation.
Management is focused on achieving organic sales growth of 2.0% to 3.0% for 2026, which aligns with recent performance. However, there is a moderate risk of missing guidance, as past earnings surprises have been trending down.
The thesis hinges on the ability of SOLV to maintain its guidance and the performance of key sector peers like ISRG, BDX, and RMD. Additionally, any changes in the jobs report could impact sentiment in the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, SOLV's performance will depend on management execution and sector dynamics. Not investment advice.
